Welcome to the real world

pharmafile | August 21, 2008 | Feature | Research and Development |  clinical trials, design, observational, phase III 

Related Content

Most advanced breast cancer patients treated in community settings, Phesi study finds

Most patients with advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer are treated in community settings …

Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison

Pharmaceutical firm Lilly’s orforglipron was associated with greater reductions in body weight and blood glucose …

AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials

AstraZeneca’s tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) in two …

The Gateway to Local Adoption Series

Latest content